<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379039</url>
  </required_header>
  <id_info>
    <org_study_id>MORRIS_1</org_study_id>
    <nct_id>NCT02379039</nct_id>
  </id_info>
  <brief_title>Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer</brief_title>
  <acronym>MORRIS</acronym>
  <official_title>Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer in Head &amp; Neck, Lung, Oesophagus, Anal Canal and Uterine Cervix - a Basis for Personalised Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's aim is to define imaging and molecular bio-markers for prediction of radiotherapy&#xD;
      response of squamous cell carcinomas, in an early treatment phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with squamous cell carcinoma of the head &amp; neck, anal canal, cervix, esophagus or&#xD;
      lung will be assessed before start of radiotherapy and 1-2 weeks after start.&#xD;
      Multi-parametric MRI and 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (18F-FDG) positron&#xD;
      emission tomography (PET) will be performed in parallel to metabolomic analyses of tumour&#xD;
      tissue. The investigators will correlate changes in imaging bio-markers to corresponding&#xD;
      changes in tissue or blood bio-markers by repeated imaging and biopsies for better&#xD;
      understanding of the image parameters.&#xD;
&#xD;
      The data from the two assessments will be used for identifying imaging bio-markers,&#xD;
      predictive for outcome. The patient data will be divided into one set of data for hypothesis&#xD;
      generation and another set for validation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Loco regional control</measure>
    <time_frame>2 years</time_frame>
    <description>After completion of radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Loco regional tumour control (response)</measure>
    <time_frame>2 months</time_frame>
    <description>After completion of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of failure</measure>
    <time_frame>2 years</time_frame>
    <description>Time and location of recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>After completion of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in imaging and metabolic data</measure>
    <time_frame>1-2 weeks</time_frame>
    <description>As measured 1-2 weeks after start of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Site specific toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Measured as patient reported side-effects</description>
  </secondary_outcome>
  <enrollment type="Anticipated">412</enrollment>
  <condition>Squamous Carcinoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Anal Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Cervix Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumour biopsies, plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with previously untreated squamous carcinoma aimed for radiotherapy with curative&#xD;
        intent of the oral cavity, oropharynx, uterine cervix, oesophagus, anal canal or lung.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Morphologically (pathology or cytology) verified, previously untreated squamous cell&#xD;
             carcinoma (SCC) of the oral cavity, oropharynx, uterine cervix, oesophagus or lung.&#xD;
&#xD;
          2. The patient should be planned for treatment with radiotherapy alone or in combination&#xD;
             with concomitant medical therapy&#xD;
&#xD;
          3. The tumour shall be radiologically and/or visually identifiable and accessible for&#xD;
             biopsy without the need for general anaesthesia or other major interventions&#xD;
&#xD;
          4. The patient must be at least 18 years of age, able to understand the given information&#xD;
             and, leave a written informed consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient is unwilling to participate in the study&#xD;
&#xD;
          2. Patients with adjuvant post-operative radiotherapy (i.e. no visible remaining tumour)&#xD;
&#xD;
          3. Pregnancy or lactation&#xD;
&#xD;
          4. Contraindications to investigations with MRI, gadolinium contrast or PET-tracers&#xD;
&#xD;
          5. Patients with an estimated glomerular filtration rate (GFR) &lt;60 ml/min/1.73m2.&#xD;
&#xD;
          6. Severe co-morbidities that are judged to significantly compromise survival in a&#xD;
             two-years perspective.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Björn Zackrisson, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University, Department of Radiation Sciences - Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Björn Zackrisson, Professor</last_name>
    <phone>+46907850000</phone>
    <phone_ext>1564</phone_ext>
    <email>bjorn.zackrisson@umu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Söderström, MD</last_name>
    <phone>+46907850000</phone>
    <email>karin.soderstrom@onkologi.umu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Umeå University</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin E Söderström, MD</last_name>
      <phone>7850000</phone>
      <email>karin.soderstrom@onkologi.umu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>If relevant, anonymized data may be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will become available 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Metaanalysis, comprehensive review. Request is sent to principal investigator (Bjorn Zackrisson)</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02379039/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

